ClinicalTrials.gg

Program

BL-M24D1

Its studies are mostly in Multiple Myeloma · Digestive System Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since Nov 14, 20254 company-led studies, 4 open or runningNext primary completion: Nov 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical44 open or runningphase 1since Nov 14, 2025Nov 14, 2025Nov 2027phase 1 · NCT07232524

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First studies: 3 phase 1 studiesFirst studyNCT07232524, NCT07232420, NCT07255898
  2. Dec 1, 2025Phase 1 study in Digestive System NeoplasmsNCT07279428 · 33 planned · China

Ahead

  1. Nov 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT07232524
  2. Dec 2027Primary completion: phase 1 study in Digestive System NeoplasmsNCT07279428
  3. Dec 2027Primary completion: phase 1 study in Multiple MyelomaNCT07255898
  4. Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07232420

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07279428Digestive System Neoplasms · China1RecruitingDec 202733
NCT07255898Multiple Myeloma · China1RecruitingDec 202733
NCT07232524Squamous Cell Carcinoma of Head and Neck · China1RecruitingNov 202716
NCT07232420Carcinoma, Non-Small-Cell Lung · China1RecruitingDec 202733

How it is read

Names in the registry

  • “BL-M24D1”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.